Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
Read More
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023
Read More
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
May 30, 2023
Read More
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
May 23, 2023
Read More
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
Read More
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
April 17, 2023
Read More
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
March 23, 2023
Read More
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023
Read More
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
February 3, 2023
Read More
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
January 9, 2023
Read More
Displaying 1 - 10 of 11